Merck & Company, Inc. (MRK) Price Target Lowered to $59.00 at Deutsche Bank AG
Merck & Company, Inc. (NYSE:MRK) had its price target lowered by analysts at Deutsche Bank AG from $62.00 to $59.00 in a research note issued to investors on Friday. The firm currently has a “hold” rating on the stock. Deutsche Bank AG’s target price points to a potential upside of 8.52% from the stock’s current price.
A number of other equities analysts have also recently issued reports on the company. Jefferies Group LLC reissued a “sell” rating and issued a $52.00 price target on shares of Merck & in a research note on Sunday, August 20th. BMO Capital Markets reissued a “buy” rating and issued a $72.00 price target on shares of Merck & in a research note on Friday, September 8th. Credit Suisse Group decreased their price target on Merck & from $75.00 to $74.00 and set an “outperform” rating for the company in a research note on Wednesday, August 30th. SunTrust Banks, Inc. cut Merck & from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. Finally, Zacks Investment Research cut Merck & from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and ten have assigned a buy rating to the company. Merck & currently has an average rating of “Hold” and an average target price of $66.44.
Shares of Merck & (MRK) opened at $54.37 on Friday. The firm has a market capitalization of $148,127.64, a price-to-earnings ratio of 13.98, a PEG ratio of 2.34 and a beta of 0.78. The company has a current ratio of 1.43, a quick ratio of 1.16 and a debt-to-equity ratio of 0.57. Merck & has a 1 year low of $53.63 and a 1 year high of $66.80.
Merck & (NYSE:MRK) last announced its quarterly earnings data on Friday, October 27th. The company reported $1.11 earnings per share for the quarter, topping the consensus estimate of $1.03 by $0.08. Merck & had a return on equity of 27.08% and a net margin of 11.60%. The business had revenue of $10.33 billion during the quarter, compared to the consensus estimate of $10.54 billion. During the same period in the prior year, the company earned $1.07 EPS. Merck &’s revenue for the quarter was down 2.0% on a year-over-year basis. sell-side analysts anticipate that Merck & will post 3.95 earnings per share for the current year.
In other Merck & news, Director Thomas H. Glocer sold 5,000 shares of the stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $56.20, for a total value of $281,000.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.25% of the stock is currently owned by corporate insiders.
Hedge funds have recently bought and sold shares of the company. Chicago Partners Investment Group LLC lifted its holdings in Merck & by 1,394.7% during the third quarter. Chicago Partners Investment Group LLC now owns 5,366 shares of the company’s stock worth $344,000 after acquiring an additional 5,007 shares during the period. Institutional & Family Asset Management LLC increased its position in Merck & by 4.0% in the third quarter. Institutional & Family Asset Management LLC now owns 55,845 shares of the company’s stock worth $3,576,000 after buying an additional 2,152 shares during the last quarter. Steward Partners Investment Advisory LLC purchased a new stake in Merck & in the third quarter worth $4,922,000. Public Employees Retirement System of Ohio increased its position in Merck & by 0.4% in the third quarter. Public Employees Retirement System of Ohio now owns 1,916,777 shares of the company’s stock worth $122,731,000 after buying an additional 6,997 shares during the last quarter. Finally, Coastline Trust Co increased its position in Merck & by 5.5% in the third quarter. Coastline Trust Co now owns 60,579 shares of the company’s stock worth $3,878,000 after buying an additional 3,180 shares during the last quarter. Institutional investors own 72.98% of the company’s stock.
About Merck &
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.